Alligator Bioscience AB (LTS:0RK9)
kr 1.256 0 (0%) Market Cap: 934.77 Mil Enterprise Value: 869.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 33/100

Alligator Bioscience AB at AACR Virtual Annual Meeting Transcript

Apr 27, 2020 - Apr 28, 2020 / NTS GMT
Release Date Price: kr1.93
Charlotte Russell
Alligator Bioscience AB - Chief Medical Officer

I'm Charlotte Russell, Chief Medical Officer. On behalf of the investigators and my colleagues at Alligator Bioscience, I'm happy to present the interim data from the first-in-human Phase 1 dose-escalation study with ATOR-1015 in patients with advanced solid malignancies.

ATOR-1015 is a human bispecific antibody targeting CTLA-4 and OX40. It was developed by fusing an optimized version of CD86, one of the natural ligands to CTLA-4, to an agonistic OX40 antibody in an IgG1 format. Both CTLA-4, a checkpoint receptor expressed on regulatory T cells, and OX40, a co-stimulatory receptor on the T cells, are highly upregulated in the tumor microenvironment. So, by targeting these two receptors, ATOR-1015 has the potential to increase localization to the tumor area compared to monospecific antibodies.

The tumor localization of ATOR-1015 may reduce the risk of systemic T-cell activation and improve the efficacy. The mode of action of ATOR-1015 has been evaluated in vitro where it induces T-cell activation and depletes

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot